Scholarlink

Background <p>Dumping syndrome is a common complication following metabolic and bariatric surgery (MBS) and is associated with significant morbidity and impaired quality of life. While glucagon-like peptide-1 receptor modulators (GLP-1 RMs) are established therapies for obesity, their role in the management of dumping syndrome remains unclear. Existing literature is limited and has largely focused on postprandial hypoglycaemia as a surrogate for late dumping syndrome.</p> Objective <p>To map the current evidence regarding the safety and efficacy of GLP-1 RMs in the management of dumping syndrome following MBS, recognising dumping syndrome as a broader clinical entity encompassing symptoms, quality of life, and glucose stabilisation.</p> Methods <p>A scoping review was conducted in accordance with Joanna Briggs Institute methodology and reported using PRISMA-ScR guidelines. A comprehensive search of multiple databases was performed to identify peer-reviewed clinical studies evaluating GLP-1 RMs for dumping syndrome after MBS. Data were extracted on study design, patient characteristics, type of dumping syndrome, GLP-1 RM regimen, and clinical outcomes.</p> Results <p>Fifteen studies involving 107 patients were included - predominantly case reports and case series. GLP-1 receptor agonist therapy was associated in these cases with reduction or resolution of hypoglycaemic episodes and improvement in dumping-related symptoms. Limited evidence also suggested improvements in quality of life. The GLP-1 receptor antagonists in small studies showed some stabilisation of postprandial glucose profiles and attenuating exaggerated insulin responses. Adverse effects were poorly recorded but appeared well tolerated in short term studies.</p> Conclusions <p>Current evidence suggests a potential role for GLP-1 RMs in the management of both early and late dumping syndrome following MBS. However, the evidence base is limited by small sample sizes, heterogeneous diagnostic criteria, and variable outcome reporting. High-quality, prospective studies using standardised definitions and diagnostic approaches are required to clarify efficacy, safety, and long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of Glucagon-like Peptide 1 Receptor Modulators for the Management of Dumping Syndrome in Patients Who have Undergone Metabolic and Bariatric Surgery: a Scoping Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Madeline Rogers-Seeley,
  • Natalie Guiney,
  • Khang Duy Ricky Le

摘要

Background

Dumping syndrome is a common complication following metabolic and bariatric surgery (MBS) and is associated with significant morbidity and impaired quality of life. While glucagon-like peptide-1 receptor modulators (GLP-1 RMs) are established therapies for obesity, their role in the management of dumping syndrome remains unclear. Existing literature is limited and has largely focused on postprandial hypoglycaemia as a surrogate for late dumping syndrome.

Objective

To map the current evidence regarding the safety and efficacy of GLP-1 RMs in the management of dumping syndrome following MBS, recognising dumping syndrome as a broader clinical entity encompassing symptoms, quality of life, and glucose stabilisation.

Methods

A scoping review was conducted in accordance with Joanna Briggs Institute methodology and reported using PRISMA-ScR guidelines. A comprehensive search of multiple databases was performed to identify peer-reviewed clinical studies evaluating GLP-1 RMs for dumping syndrome after MBS. Data were extracted on study design, patient characteristics, type of dumping syndrome, GLP-1 RM regimen, and clinical outcomes.

Results

Fifteen studies involving 107 patients were included - predominantly case reports and case series. GLP-1 receptor agonist therapy was associated in these cases with reduction or resolution of hypoglycaemic episodes and improvement in dumping-related symptoms. Limited evidence also suggested improvements in quality of life. The GLP-1 receptor antagonists in small studies showed some stabilisation of postprandial glucose profiles and attenuating exaggerated insulin responses. Adverse effects were poorly recorded but appeared well tolerated in short term studies.

Conclusions

Current evidence suggests a potential role for GLP-1 RMs in the management of both early and late dumping syndrome following MBS. However, the evidence base is limited by small sample sizes, heterogeneous diagnostic criteria, and variable outcome reporting. High-quality, prospective studies using standardised definitions and diagnostic approaches are required to clarify efficacy, safety, and long-term outcomes.